BioCentury | Nov 15, 2019
Financial News

Atomwise JV raises $14.5M series A to advance AI-discovered candidates

X-37 raised a $14.5 million series A to move forward AI platform-generated programs from Atomwise, which launched the JV last year with Velocity Pharmaceutical Development. DCVC Bio led Thursday’s round, with participation from Alpha Intelligence...
BioCentury | Oct 13, 2016
Translation in Brief

Zapping Tregs

A team at NIH's National Cancer Institute (NCI) has developed a phototherapy that selectively ablates Tregs in tumors to avoid the autoimmune liabilities of systemic immunotherapies. Despite their impressive efficacy, checkpoint inhibitors marketed to treat...
BioCentury | Aug 11, 2016
Product R&D

SHP-2 sets sail

Novartis AG researchers have revived a once-promising cancer target - a protein tyrosine phosphatase - by departing from the rote strategy of blocking its active site, and arresting the molecule in its inactive form instead. The company...
BioCentury | Mar 9, 2015
Strategy

Prepping for PCSK9s

By securing Priority Review for Praluent alirocumab, Sanofi and Regeneron Pharmaceuticals Inc. deprived Amgen Inc. of what could have been a three-month head start with its competing PCSK9 inhibitor. But the partners also put themselves...
BioCentury | Nov 17, 2014
Strategy

Lantus limbo

The abrupt slowing of Lantus sales in the U.S. could augur reimbursement pressure for new insulin candidates entering the market from Sanofi and its competitors. A halving of U.S. sales growth for Lantus insulin glargine...
BioCentury | Nov 17, 2014
Strategy

Poste a pourvoir

Job one for Sanofi 's next CEO will be to shore up revenues, a task that may be difficult since the board has taken major acquisitions off the table and all the products in the...
BioCentury | Oct 30, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Zinc finger CCCH-type antiviral 1 (ZC3HAV1; ZAP) In vitro and mouse studies suggest an oncolytic alphavirus could help treat cancers expressing low levels of...
BioCentury | May 8, 2014
Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Brain-derived neurotrophic factor (BDNF) gene therapy delivered to the inner ear using cochlear implants A study in guinea pigs suggests delivering gene therapy to the...
BioCentury | May 8, 2014
Tools & Techniques

Zapping hearing loss

The most advanced cochlear implants for hearing loss lack frequency resolution and dynamic range, causing recipients to perceive sounds as loud, monotonous and robotic. An Australian team may have solved those problems with a combination...
BioCentury | Nov 19, 2012
Strategy

Zapping Zaltrap

Sanofi 's decision to offer a 50% discount on Zaltrap ziv-aflibercept would appear to address oncologists' objections to the colorectal cancer drug's cost, but it is not clear whether the move will improve either patient...
Items per page:
1 - 10 of 24